Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
7.84
+0.04 (0.51%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cogent Biosciences Employees
Cogent Biosciences had 164 employees as of December 31, 2023. The number of employees increased by 26 or 18.84% compared to the previous year.
Employees
164
Change (1Y)
26
Growth (1Y)
18.84%
Revenue / Employee
n/a
Profits / Employee
-$1,477,421
Market Cap
866.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 164 | 26 | 18.84% |
Dec 31, 2022 | 138 | 61 | 79.22% |
Dec 31, 2021 | 77 | 62 | 413.33% |
Dec 31, 2020 | 15 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Aveanna Healthcare Holdings | 33,500 |
AMN Healthcare Services | 3,585 |
Phibro Animal Health | 1,940 |
AbCellera Biologics | 586 |
Paragon 28 | 574 |
Immatics | 535 |
uniQure | 480 |
Prothena Corporation | 173 |
COGT News
- 12 days ago - Why Is Cogent Biosciences Stock Trading Higher On Monday? - Benzinga
- 12 days ago - Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - GlobeNewsWire
- 13 days ago - Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) - GlobeNewsWire
- 6 months ago - Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 7 months ago - Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - GlobeNewsWire
- 7 months ago - Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting - GlobeNewsWire
- 8 months ago - Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 9 months ago - Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor - GlobeNewsWire